# Nuclide record telix (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/telix/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "telix" ;
  schema:name "Telix Pharmaceuticals"@en ;
  schema:description "Telix is the Australian theranostics company behind Illuccix and Gozellix PSMA imaging and a broad therapeutic pipeline."@en ;
  schema:url <https://nuclide.cc/companies/telix/>, <https://telixpharma.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://telixpharma.com>, <https://telixpharma.com/news-views/telix-and-regeneron-announce-strategic-radiopharma-collaboration/>, <https://telixpharma.com/news-views/telix-q2-2026-revenue-us247m-strong-momentum-and-pipeline-progress/>, <https://www.sec.gov/Archives/edgar/data/2007191/000200719125000003/frelease.htm>, <https://telixpharma.com/our-pipeline/> ;
  schema:addressCountry "AU" ;
  nuclide:related <https://nuclide.cc/indications/sclc/>, <https://nuclide.cc/indications/nsclc/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/zr-89/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/targets/dll3/> ;
  nuclide:drugs <https://nuclide.cc/drugs/girentuximab-zr89/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06520345/>, <https://nuclide.cc/trials/nct07052214/> .